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Marine n−3 polyunsaturated fatty acids (PUFA) may have beneﬁcial effects in relation
to atrial ﬁbrillation (AF) with promising data from experimental animal studies, however,
results from studies in humans have been inconsistent. This review evaluates the mech-
anisms of action of marine n−3 PUFA in relation to AF based on experimental data and
provides a status on the evidence obtained from observational studies and interventional
trials. In conclusion, there is growing evidence for an effect of marine n−3 PUFA in preven-
tion and treatment of AF. However, further studies are needed to establish which patients
are more likely to beneﬁt from n 3 PUFA, the timing of treatment, and dosages.−
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INTRODUCTION
Faced with the growing epidemic of atrial ﬁbrillation (AF), there
is an unmet need for preventive measures as well as better treat-
ment of this disorder. Some of the advances in recent years have
been on rhythm control to restore sinus rhythm, but the devel-
opment of effective and safe drugs for restoring sinus rhythm has
been difﬁcult, trying to balance beneﬁcial anti-arrhythmic effects
with risk of pro-arrhythmic adverse effects. Invasive intervention
by catheter ablation techniques and surgery may be more effec-
tive, but is an option mostly for highly symptomatic patients,
given the risk of peri-procedure complications and high costs.
Fish consumption and intake of marine n−3 polyunsaturated
fatty acids (PUFA), with suggested anti-arrhythmic effects in rela-
tion to malignant ventricular arrhythmias, is safe and with few
side-effects.
This review will discuss the mechanisms of action of marine
n−3 PUFA in relation to AF based on experimental data and pro-
vide a status on the evidence of the effect of marine n−3 PUFA
in AF as obtained from observational studies and interventional
trials.
BACKGROUND
FISH, MARINE n−3 PUFA, AND CARDIAC DISEASE
In early studies of Greenland natives, Bang, and Dyerberg found
a lower risk of death from coronary heart disease (Dyerberg
et al., 1978). The Greenland Eskimos were living on a diet con-
sisting largely on whales, seals, and ﬁsh, thus consuming around
10–14 g/day of marine n−3 PUFA, whereas most western popu-
lations consume less than 0.5 g/day (De Caterina, 2011). Several
epidemiological studies have conﬁrmed the ﬁnding in Greenland
Eskimos, although data are not entirely consistent (Bjerregaard
et al., 2010;DeCaterina, 2011;Mozaffarian andWu,2011).Marine
n−3 PUFA may affect the risk of cardiovascular disease by a
long list of mechanisms including a lowering of triglycerides, a
reduction in blood pressure, together with antithrombotic and
anti-inﬂammatory effects (De Caterina, 2011; Mozaffarian and
Wu, 2011). Furthermore, in some studies marine n−3 PUFA have
lowered the risk of sudden cardiac death (De Caterina, 2011;
Mozaffarian andWu, 2011) and in turn, these observed effects on
ventricular tachyarrhythmia have lead to research into potential
effects of n−3 PUFA on atrial rhythm disturbances including AF.
MARINE n−3 PUFA
Polyunsaturated fatty acids are divided into n−3 (omega-3) and
n−6 according to the position of the ﬁrst double bond. Both
groups are essential fatty acids, and therefore the content in the
human body is (almost) fully dependent on dietary intake. The
n−3 PUFA family consists of alpha-linolenic acid (ALA) derived
from plants and the marine n−3 PUFA consisting of eicosapen-
taenoic acid (EPA), docosahexaenoic acid (DHA), and docosapen-
taenoic acid (DPA).Marine n−3 PUFA aremost abundant in fatty
ﬁsh and in the liver of lean ﬁsh (Calder, 2012). In addition to their
dietary intake, EPA, DHA, and DPA can be synthesized endoge-
nously from ALA but only to a very limited extent (Burdge and
Calder, 2005). The biologically most important n−3 PUFA are
thought to be EPA and DHA, while very little is known about the
effect of DPA.
ATRIAL REMODELING
Atrial remodeling is deﬁned as anypersistent change in atrial struc-
ture or function (Nattel et al., 2008) that may occur either as a
substrate induced by another underlying condition or secondary
to AF itself. For AF to develop, some fundamental arrhythmia
mechanisms are required; both a suitable substrate and some form
of triggering activity, and these, in turn, facilitate and initiate reen-
try of electrical impulses, thereby maintaining AF (Nattel et al.,
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2008). Atrial remodeling can increase the potential for ectopic and
reentrant activity by a variety of mechanisms (Nattel et al., 2008).
Ectopic ﬁring provides a trigger for reentry, but may also in
itself maintain AF in the case of a rapid ectopic ﬁring focus (Nat-
tel et al., 2008). Abnormalities in cellular Ca2+ handling can cause
ectopic ﬁring, e.g., because of delayed after-depolarizations related
to Ca2+ overload.
Ischemia, inﬂammation, and dilation make atria more vulner-
able to AF (Nattel et al., 2008). For reentry to be maintained, the
cells must have regained their excitability when the impulse has
traversed the circuit, and therefore reentry is favored by short-
ening of the refractory period (e.g., by rapid atrial activation in
AF), slow conduction of the impulse (e.g., by changes in cellular
and tissue structure including ﬁbrosis), and longer distance of the
impulse circuit (e.g., atrial enlargement). The ﬁbrillatory activity
may occur either because of an irregular atrial response to a sin-
gle reentry circuit or because of multiple simultaneous functional
reentry circuits (Nattel et al., 2008).
Atrial remodeling can be divided into twomajor groups accord-
ing to whether it is related to a rapid atrial rate such as in AF, or
caused by an underlying condition. Rapid atrial tachycardia results
in shortening of the atrial refractory period (electrical remodel-
ing), occurs within the ﬁrst few days of AF, and is reversed within
1week after reversion to sinus rhythm (Allessie et al., 2002). Sec-
ondly,AF also results in impaired contractility (contractile remod-
eling) of the atria after reversion to sinus rhythm and depending
on the durationof AF,and recovery is slower lasting days tomonths
(Allessie et al., 2002). Atrial structural remodeling refers to struc-
tural changes in the atria and may occur either during prolonged
atrial tachycardia or caused by different cardiac pathologies such
as hypertensive heart disease, heart failure, myocardial infarction,
and cardiomyopathy. It includes histological changes in the atrial
myocytes in terms of dedifferentiation, and the associated atrial
ﬁbrosis causes intra-atrial conduction disturbances (Allessie et al.,
2002). AF increases dramatically with older age, which is likely in
part mediated by age-related ﬁbrosis, changes in conduction, and
increased likelihood of block (Dun and Boyden, 2009).
METHODS
SEARCH FOR LITERATURE
We searched PubMed using the MesH terms “AF” and (“Seafood,”
“FattyAcids,Omega-3,”“FishOils,”“Fishes,”or“Dietary Fats”) and
EMBASE using the terms“heart atrium ﬁbrillation”and (“omega-
3 fatty acid,” “sea food,” “ﬁsh oil,” or “exp ﬁsh”). Reference lists
from identiﬁed reports were checked for additional publications.
Criteria for consideration were publications in English published
until February 2012. All identiﬁed abstracts were assessed, and rel-
evant published reports were identiﬁed.We discarded results only
published as abstracts.
MARINE n−3 PUFA AND CARDIAC ARRHYTHMIAS
MECHANISMS OF ACTION
The effects of marine n−3 PUFA in relation to ventricular arrhyth-
mia have been extensively studied whereas few have studied the
effects on atrial myocytes. For this reason, some mechanisms of
action related to ventricular arrhythmia are summarized in order
to further suggest possible effects of n−3 PUFAon atrialmyocytes.
As recently reviewed (Saravanan et al., 2010b;Mozaffarian andWu,
2011), n−3 PUFA have beneﬁcial effects on various cardiovascu-
lar risk factors, inﬂammation, and effects related to arrhythmia via
several mechanisms including effects on cell and organelle mem-
brane structure and function; ion channels and electrophysiology;
and nuclear receptors and transcription factors.
Anti-arrhythmic effects of a diet rich in marine n−3 PUFA
were studied in a rat model byMcLennan (1993) where these fatty
acids were shown to prevent ventricular ﬁbrillation in rats, and,
in similar experiments in marmoset monkeys, they increased the
thresholds for ventricular ﬁbrillation (McLennan et al., 1993).
Likewise, subsequent studies of intravenous infusion of n−3
PUFA in a dog model of ventricular arrhythmia showed that
ventricular ﬁbrillation was much more difﬁcult to elicit after
infusion of marine n−3 PUFA (Billman et al., 1999). In a
series of in vitro studies, Leaf et al. (Leaf et al., 2005; Xiao
et al., 2005) demonstrated anti-arrhythmic effects of marine n−3
PUFA. Thus, n−3 PUFA affect numerous ion channels such as
inhibitory effects on the inward sodium current (INa) and l-
type inward calcium current (ICa,L) which may be important
for their anti-arrhythmic effects (Leaf et al., 2005). n−3 PUFA
affect the INa by shifting the steady-state inactivation to hyper-
polarized potentials and thereby prolonging the refractory period
(Xiao et al., 1998, 2000). Inhibition of ICa,L by n−3 PUFA (Xiao
et al., 1997) prevents triggering activity from after-potential dis-
charges caused by excessive cytosolic Ca2+ ﬂuctuations (Leaf
et al., 2005). Also, n−3 PUFA have electrical stabilizing effects
on myocytes as shown in vitro (Kang and Leaf, 1996) where
myocytes added EPA showed reduced spontaneous beating rate
and required higher electrical stimulation to contract (Leaf et al.,
2005).
ACUTE VS. CHRONIC EFFECTS
n−3 PUFA may principally operate in at least two different ways,
either circulating in the blood or after incorporation into cells.
Studies on circulating n−3 PUFA typically have used experimen-
tal designs where n−3 PUFA is added intravenously or in vitro in
cellular studies and may thus be termed “acute effects,” whereas
“chronic effects” reﬂect dietary exposure over time where n−3
PUFA is incorporated into cellular membranes in addition to a
steady-state of circulating n−3 PUFA (comparatively less than
when administered intravenously). The period to full incorpora-
tion of n−3 PUFAhas been reported to be 28 days formyocardium
content of DHA in rats (Owen et al., 2004), 12weeks for incorpo-
ration of EPA and DHA in right atrium and left ventricle in dogs
(Billman et al., 2010), and 30 days for DHA and EPA in right atrial
appendage tissue in humans (Metcalf et al., 2007). Importantly,
“acute effects” of circulating n−3 PUFA have been shown to be
different from “chronic effects” of n−3 PUFA in cellular mem-
branes, which include different effects on various ion channels as
reviewed by Den Ruijter and Coronel (2009). For example, cir-
culating n−3 PUFA inhibit INa and ICa,L, whereas n−3 PUFA
incorporated into cellular membranes do not affect INa, but both
inhibit ICa,L and the reopening of the calcium channel at plateau
potentials. Thus, when interpreting clinical studies on n−3 PUFA,
it is important to distinguish between studies on acute intravenous
and long-term dietary exposure.
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POTENTIAL MECHANISMS
Among these general effects on cardiac arrhythmia, some mech-
anisms may be of particular interest in relation to AF. Some
mechanisms underlying AF include triggering activity by rapidly
ﬁring focal ectopic sources (often from the pulmonary veins) and
reentry mechanisms including functional reentry circuits (proba-
bly more predominant in early stages such as paroxysmal AF) and
multiple-circuit reentry (probably related to more pronounced
structural remodeling in patients with persistent AF). n−3 PUFA
reduce triggering activity and may affect reentry mechanisms in
ventricular myocytes (Den Ruijter et al., 2007), and similar effects
may occur in atrialmyocytes (Nattel andVanWagoner, 2011). This
is, however, yet to be established.
Also, marine n−3 PUFA affect risk factors for ischemic heart
disease such as lowering of blood pressure and plasma triglyc-
erides and have anti-inﬂammatory effects, as they compete directly
with n−6 PUFA as substrates for inﬂammatory eicosanoids,
with the n−3-derived leukotrienes and thromboxanes being less
inﬂammatory than products derived from n−6 PUFA (Calder,
2006).
Thus, the effects of marine n−3 PUFAonAFmay be viamecha-
nisms related to atherosclerosis and ischemic heart disease, includ-
ing anti-inﬂammatory effects as well as direct anti-arrhythmic
effects on myocytes through effects on ion channels, electrical
stabilizing effects, and ﬂuidity of the cell membrane.
EXPERIMENTAL ANIMAL STUDIES
In an in vitro model, induction of asynchronous contractile activ-
ity by a β-adrenoceptor stimulus in rat atrialmyocyteswas reduced
by addition of DHA and EPA, while cell membrane ﬂuidity was
increased (Jahangiri et al., 2000). Also, EPA reduced arrhythmo-
genesis in isolated rabbit pulmonary vein tissue via nitric oxide
production (Suenari et al., 2011).
Electrical remodeling by reduction of atrial refractory period is
an important early remodeling event that favors the development
and maintenance of AF. In a model of stretch-induced vulnerabil-
ity of AF, rabbits fed n−3 PUFAwere less susceptible to induce and
sustain AF and also had less stretch-induced shortening of atrial
refractory period (Ninio et al., 2005). Infusion of n−3 PUFA sig-
niﬁcantly reduced the shortening of atrial refractory period in
an experimental model on dogs receiving rapid atrial pacing (da
Cunha et al., 2007), whereas this was not found in a different study
on dogs fed n−3 PUFA for a longer duration (Sakabe et al., 2007).
Effects on structural remodeling were investigated in a ventricu-
lar tachypacing model of congestive heart failure. Dogs fed n−3
PUFA developed less atrial structural remodeling in terms of atrial
ﬁbrosis and conduction abnormalities as well as shorter duration
of burst pacing-induced AF (Sakabe et al., 2007). Similar results
were found in rabbits fed a diet of puriﬁed EPAwhich showed sup-
pression of atrial structural remodeling with less cardiac ﬁbrosis,
shorter duration of inducedAF, as well as a less inﬂammatory pro-
ﬁle in atrial and epicardial adipose tissues (Kitamura et al., 2011).
Also, in a model with 2weeks of simultaneous atrioventricular
pacing, dogs fed n−3 PUFA had less AF inducibility and shorter
episodes of AF, reduced conduction anisotropy in the left atrium,
and prevention of pacing-induced increase in collagen turnover
and collagen deposition in atrial appendage (Laurent et al., 2008).
Furthermore, there was a beneﬁcial effect on genes related to
ﬁbrosis, hypertrophy, and inﬂammation (Ramadeen et al., 2010).
In a model of post-operative AF in dogs fed n−3 PUFA for
3weeks before excision of the left atrial appendage, AF was not
inducible (0/7) compared to induction in four of six control
animals. In addition, n−3 PUFA-treated animals had longer post-
operative atrial effective refractory period, increased heart rate
variability, and reduced atrial inﬂammation (Mayyas et al., 2011).
Likewise, in a model of AF induced by sterile pericarditis, dogs
fed n−3 PUFA for 4weeks had less inﬂammation and reduced
inducibility and maintenance of AF (Zhang et al., 2011). Finally,
in a model of vagally induced AF, dogs fed n−3 PUFA were less
vulnerable to develop AF (Sarrazin et al., 2007).
Given the multiple disposing factors for developing AF with
older age in humans, the type of experimentally induced AF in
different animal models is a major limitation for interpreting the
results in addition to the inherent differences between species.
Also, acute effects of n−3 PUFA are tested by in vitro or intra-
venous administration of n−3 PUFA, whereas chronic effects are
investigated in themodelswhere animals havebeen fedn−3PUFA.
However, while the reported effects of treatment in these mod-
els suggest that they may serve as a useful tool for investigating
possible effects of n−3 PUFA in relation to AF, human studies
are needed to establish whether marine n−3 PUFA are clinically
useful in this population.
Taken together, data from animal studies on AF show convinc-
ing results with a substantial effect of n−3 PUFA, and for some
parameters there is almost a complete reduction of the differ-
ences induced in the experimental models. Thus, the effects of
n−3 PUFA in these studies include reduction in the shortening of
atrial refractory period (electrical remodeling), reduction of atrial
ﬁbrosis (structural remodeling), reduction of post-operative AF
(inﬂammation), and a reduction in vagally induced AF.
PRIMARY PREVENTION OF AF
A number of observational studies have addressed whether intake
of ﬁsh and marine n−3 PUFA was associated with a lower risk
of developing AF (Table 1). Promising data on ﬁsh consump-
tion and prevention of AF were originally found in a prospective
cohort from the Cardiovascular Health Study (Mozaffarian et al.,
2004). The 4815 study participants were 65 years or older, and
during 12 years of follow-up, 980 incident cases of AF occurred.
Consumption of tuna or other broiled or baked ﬁshwas associated
with a 28% lower risk of AF with intake one to four times per week
(HR 0.72, 95% CI 0.58–0.91, p = 0.005), and 31% lower risk with
intake ≥5 times per week (HR 0.69, 95% CI 0.52–0.91, p = 0.008),
compared to intake less than once per month. In contrast, con-
sumption of fried ﬁsh or ﬁsh sandwiches was not correlated to
plasma n−3 PUFA levels and was suggestive of a higher risk of AF
although not statistically signiﬁcant. These types of ﬁsh primarily
include lean ﬁsh and in addition, themethod of cooking inﬂuences
the fatty acid content as frying has been reported to affect the fat
content whereas the formation of oxidized cholesterol products is
further increased by roasting (Echarte et al., 2001). Similar results
were found in a Finnish prospective cohort study from the Kuopio
Ischemic Heart Disease Risk Factor Study (Virtanen et al., 2009)
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where a total of 240 incident cases of AF occurred during 18 years
of follow-up among 2174 men aged between 42 and 60 years. The
highest quartile of total n−3 PUFA content in serum at baseline
was associated with a 35% lower risk of AF compared to the lowest
quartile (HR 0.65, 95% CI 0.44–0.96, p for trend= 0.07). Serum
DHA (but not EPA) was associated with the risk of AF, with a 38%
lower risk of AF comparing the highest and lowest quartiles (HR
0.62, 95% CI 0.42–0.92, p for trend= 0.02). This inverse associa-
tion has, however, not been found in other cohort studies (Frost
andVestergaard, 2005; Brouwer et al., 2006; Berry et al., 2010; Shen
et al., 2011). Thus, in the study by Frost and Vestergaard (2005),
there was a signiﬁcantly higher risk of AF when comparing the
highest vs. the lowest quintile of n−3 PUFA consumption. In an
exploratory analysis in the study by Shen et al. (2011), the high-
est intake of dark (fatty) ﬁsh was also associated with a higher
risk of AF. Overall, these studies have shown no clear association
between higher ﬁsh or n−3 PUFA intake and incident AF. Finally,
an Italian registry-based study on prescription of ﬁsh oil supple-
ments for patients discharged after amyocardial infarction showed
that signiﬁcantly fewer had AF within the next year in the group
prescribed ﬁsh oil supplements (Macchia et al., 2008).
Differences exist between the studies that may explain some
of these contradictory results. The participants in the study by
Mozaffarian et al. (2004) were older compared to the other stud-
ies, and the effects of ﬁsh intake may be more effective in this age
category. First, the background diet in the population as well as
the available ﬁsh products differ between studies Next, the causes
of AF may differ between the study populations, and therefore
the susceptibility to the effects of marine n−3 PUFA may dif-
fer. Also, patients may be motivated to a higher ﬁsh intake, for
instance because of symptomatic coronary heart disease, and this
would select persons who have higher morbidity and a higher
a priori risk of AF, which in turn would bias the results in the
direction of a detrimental effect of intake. It may also be that the
effect, if any, of ﬁsh and ﬁsh oils is not simply a linear dose–
response but may instead have a different association such as
threshold effect or even a U- or J-shaped effect with detrimen-
tal impacts at both very low and very high levels. If a threshold
effect is indeed present, establishing this would be very much
dependent on the distribution of intake in the study popula-
tion. Larger studies would be helpful in clarifying these issues,
e.g., by using continuous exposure measures such as cubic splines.
Although primary prevention of AF is of major importance, it is
not likely that it would be feasible to conduct a RCT since this
would require a very large study. For this reason, exploring a pos-
sible effect on primary prevention will be much dependent on
further epidemiological studies.
PREVENTION OF RECURRENCE OF AF AFTER CARDIOVERSION
Although primary prevention of AF is very important for reduc-
ing the AF burden in a population, it is more feasible to motivate
patients for secondary prevention of AF, where there is a need for
safe and well-tolerated treatment options. As this setting is differ-
ent, with varying degrees of electrical and structural remodeling
ongoing or ﬁnalized, an effect of treatment may work by different
mechanisms compared to the setting of primary prevention where
effects on cardiovascular risk factors such as hypertension may be
more predominant. For this reason, it is important to consider the
type of patients when comparing results from different studies.
Recently, a number of RCT has been reported (Table 2), of
which two showed a beneﬁcial effect of treatment with marine
n−3 PUFA (Nodari et al., 2011; Kumar et al., 2012), whereas this
was not found in three other studies (Kowey et al., 2010; Bianconi
et al., 2011; Ozaydin et al., 2011).
Thus, in a study by Nodari et al. (2011), 199 patients with
persistent AF who were treated with amiodarone and a renin–
angiotensin–aldosterone system inhibitor were randomized to
1.7 gn−3PUFA/dayor placebo4weeks before electrical cardiover-
sion. The primary endpoint was maintenance of sinus rhythm
at 1-year follow-up, and of the n−3 PUFA-treated patients, 62%
were still in sinus rhythm compared to 36% in the placebo group
(p< 0.0001).
Also in favor of a beneﬁcial effect of n−3 PUFA is a recent study
by Kumar et al. (2012) involving 178 patients with persistent AF
who were randomized to 1.8 g n−3 PUFA/day or placebo for at
least 1month prior to electrical cardioversion. Primary endpoint
was recurrence of persistent AF deﬁned as AF documented for
at least 1 week. At 90 days, 39% in the n−3 PUFA group had AF
recurrence compared to 78% of controls (HR 0.38, 95% CI 0.27–
0.56, p< 0.001). At 1 year, 67% of n−3 PUFA-treated patients
and 90% of controls had persistent AF (p< 0.001). Extending the
ﬁndings by Nodari et al., n−3 PUFA were associated with a sig-
niﬁcant reduction in AF recurrence with or without concurrent
anti-arrhythmic drugs. An additional ﬁnding was that increasing
levels of DHA as a percentage of fatty acids in the phospholipid
fraction of serumpredicted a lower risk of AF recurrence (HR0.59,
95% CI 0.42–0.83, p = 0.003), whereas this was not statistically
signiﬁcant for EPA (HR 0.9, 95% CI 0.8–1.1, p = 0.08).
Contrary to these ﬁndings, no effect of treatment was found in
a large study by Kowey et al. (2010) in patients with paroxysmal
AF (n = 542) or persistent AF (n = 121) without structural heart
disease. The patients were in sinus rhythm at baseline and ran-
domized to 6.7 g n−3 PUFA/day for 7 days and 4 g/day thereafter.
There was no difference between treatment groups for recurrence
of symptomatic AF in the paroxysmal stratum (HR 1.15, 95% CI
0.90–1.46, p = 0.26), in the persistent stratum (HR 1.64, 95% CI
0.92–2.92, p = 0.09), or in both strata combined (HR 1.22, 95%CI
0.98–1.52, p = 0.08). Importantly, almost half of AF recurrences
occurred within 2weeks of n−3 PUFA supplementation. In com-
parison with the studies by Nodari et al. (2011) and Kumar et al.
(2012), it can be argued that the effect of n−3 PUFA may not be
fully penetrant this early, since it takes about 30 days for full incor-
poration of n−3 PUFA into atrial myocytes (Owen et al., 2004;
Metcalf et al., 2007). Other differences were that patients were not
on anti-arrhythmic drug treatment, had no structural heart dis-
ease, and predominantly had paroxysmal AF, and therefore a lesser
degree of atrial remodeling.
Likewise, no effect was found by Bianconi et al. (2011) in a
study of 204 patients with persistent AF randomized to 2.6 g n−3
PUFA/day or placebo starting ≥7 days (mean 3weeks) prior to
cardioversion and 2 g/day thereafter. The primary endpoint was
AF recurrence which occurred in 59% of the n−3 PUFA-treated
patients and in 51% of controls (p = 0.28). Compared to the stud-
ies by Nodari et al. (2011) and Kumar et al. (2012), a lack of effect
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of n−3 PUFA supplementation may be explained by the fact that
themajority of patients had been treated for less than 30 days prior
to cardioversion. Differences in the background diet may also be
a contributory factor, since the DHA concentration in blood only
increased by 25% which is lower than 1.8-fold in the study by
Kumar et al. (2012), suggesting a smaller difference between the
intervention group and the placebo group. Finally, a small study by
Ozaydin et al. (2011) with n−3 PUFA started after cardioversion
also found no difference between groups.
In support of an effect of n−3 PUFA supplementation in
patients with persistent AF are the results of a study on 49
patients concerning atrial mechanical function after reversal to
sinus rhythm (Kumar et al., 2011c). After reversion of persis-
tent AF (external or internal cardioversion) or persistent right
atrial ﬂutter (radiofrequency ablation) to sinus rhythm, parame-
ters of left atrial appendage function were compared immediately
before and after reversion. Consumption of 1.8 g n−3 PUFA/day
for ≥1month prior to reversion was shown to attenuate atrial
mechanical stunning after reversion of AF and right atrial ﬂutter
to sinus rhythm.
At this point, more studies are needed to establish whether the
potential beneﬁcial effect on persistent AF observed in some stud-
ies is valid. It seems important to consider≥30 days pre-treatment
with n−3 PUFA to allow for incorporation in cell membranes.
Notably, an effect on top of treatment with both amiodarone
and a renin–angiotensin–aldosterone system inhibitor has been
reported.
PREVENTION OF POST-OPERATIVE AF
Patients undergoing heart surgery such as coronary artery bypass
grafting (CABG) often develop AF after the operation. In this
setting, AF is induced by the intervention, and the mechanism
is probably mediated by the highly inﬂammatory state following
surgery.
A number of RCT have examined the effects of n−3 PUFA
in patients undergoing heart surgery, especially CABG (Table 3).
Promising results were initially published by Calo et al. (2005) in
a study of 160 patients undergoing CABG. Patients were random-
ized to 1.7 g n−3 PUFA/day or placebo ≥5 days prior to surgery
and were followed until discharge. The primary endpoint was the
development of post-operative AF, which was seen in only 15% in
the n−3 PUFA group compared to 33% of controls (p = 0.013). In
addition, the n−3 PUFA group were hospitalized for signiﬁcantly
fewer days than the controls (7.3 vs. 8.2 days, p = 0.017).
Some support for a beneﬁcial effect of n−3 PUFA was also
reported by Sorice et al. (2011) in a study of 201 patients ran-
domized to on-pump or off-pump CABG and supplement with
1.7 g n−3 PUFA/day or placebo. A signiﬁcant reduction in post-
operative AF was found in on-pump CABG patients treated with
n−3 PUFA (11.7 vs. 31.6%, OR 0.28, p = 0.01), whereas no dif-
ference was seen for n−3 PUFA in off-pump CABG patients (11.1
vs. 12.5%, OR 0.87, p = 0.84). Also, Farquharson et al. (2011)
studied 194 patients undergoing CABG or valve operating pro-
cedures who were randomized to 4.5 g n−3 PUFA/day or placebo
starting 3weeks prior to surgery. There was a 37% reduction of
post-operative AF in the intervention group, however not signiﬁ-
cant (OR 0.63, 95% CI 0.35–1.11), and a non-signiﬁcant delay in
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time to onset of AF (HR 0.66, 95% CI 0.43–1.01). Length of stay
in the intensive care unit (ICU) was signiﬁcantly decreased in the
n−3 PUFA group (ratio of means 0.71, 95% CI 0.56–0.90).
In opposition to these ﬁndings, two RCT showed no effect of
n−3 PUFA on the incidence of post-operative AF. Thus, in a study
by Saravanan et al. (2010a) of 108 patients scheduled for CABG
and randomized to 1.7 g n−3 PUFA/day or placebo and followed
for 5 days with continuous ECG, no difference in AF was found
between groups. Compared to the above studies, the deﬁnition of
AF was duration ≥30 s instead of >5 to >15min, which explains
a high rate of AF. The other study by Heidarsdottir et al. (2010) in
Iceland with 168 patients treated with CABG and/or valve surgery
and randomized to 2.2 g n−3 PUFA/day or placebo found no
difference between groups. However, the background diet in this
population was rich in cod liver oil and n−3 PUFA supplements,
and the percentage of n−3 PUFA in plasma phospholipids was
about three times higher than that reported in an Italian study
(Abbatecola et al., 2009) which may be comparable to the study
by Calo et al. (2005). For this reason, the high background intake
of n−3 PUFA and a relatively small increase in the intervention
group may explain why no effect of marine n−3 PUFA could be
demonstrated.
In a study of the acute effects of n−3 PUFA, 102 patients
undergoing CABG were randomized to intravenous infusion
100mg/kg/day of ﬁsh oil or placebo (Heidt et al., 2009). Infusion
was started at admission and continued until the end of follow-
up at transfer from the ICU. Post-operative AF occurred in 15
patients (31%) in the control group but only in 9 (17%) in the
n−3 PUFA group (p< 0.05). The n−3 PUFA-treated patients also
had a signiﬁcantly shorter stay in the ICU.
The available data seem fairly promising, but more studies are
needed to establish whether n−3 PUFA supplementation is bene-
ﬁcial in patients undergoing heart surgery. Possible effects in this
special setting of heart surgery with a high inﬂammatory response
may not be directly comparative to other settings such as primary
or secondary prevention. However, prevention of post-operative
AF by a safe and well-tolerated treatment would be a compelling
treatment option as this would reduce morbidity in these patients
as well as the time spent in hospital. For future studies, a longer
pre-operative treatment for at least 1month may be considered to
allow for a higher incorporation of n−3 PUFA into cardiac cell
membranes.
n−3 PUFA AND AF PATIENTS WITH PACEMAKERS
In a study of AF patients with dual-chamber pacemakers, Bis-
cione et al. (2005) conducted an open-label serial intervention
with 1 g n−3 PUFA/day and observation by pacemaker interro-
gation before treatment, after 4months of treatment, and after
4months of withdrawal (Table 4). A signiﬁcant reduction in num-
ber of episodes and burden of atrial tachyarrhythmia was found
during n−3 PUFA treatment. These interesting ﬁndings, however,
need to be conﬁrmed in other studies.
n−3 PUFA AND RADIO FREQUENCY ABLATION
A lower risk of early recurrence (≤8weeks) and procedural failure
(>8weeks) was reported in a nested case–control study from a
cohort of patients treated with pulmonary vein antrum ablation
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forAF (Patel et al., 2009;Table 4).Among the 1500 treated patients,
patients consuming ≥665mg of ﬁsh oil were matched with con-
trols (129 in each group). Also, in an unblinded, randomized
study on patients undergoing pulmonary vein isolation, patients
randomized to 1.8 g n−3 PUFA/day had prolonged pulmonary
venous and left atrial effective refractory periods and decreased
susceptibility to initiation of AF from within the pulmonary veins
(Kumar et al., 2011b). In comparison, the effects of n−3 PUFA
on electrophysiologic parameters were studied in a single-blinded
study of patients with supraventricular tachycardia butwithoutAF
or structural heart disease (Kumar et al., 2011a). The participants
had a low ﬁsh intake and were randomized to 1.8 g n−3 PUFA/day
for at least 1month, and effects of n−3 PUFA treatment included
lengthening of atrial refractory period, less inducible, and shorter
duration of AF.
WHY ARE RESULTS ON MARINE n−3 PUFA AND AF INCONSISTENT?
One explanation for the mixed results of the effects of n−3 PUFA
could be that the effect is not simply a linear dose–response but
may be, e.g., a threshold effect between very low intake and nor-
mal/high intake or even a J- or U-shaped effect where very low and
very high levels are detrimental, as suggested in a study on plasma
content of n−3 PUFA and post-operative AF (Skuladottir et al.,
2011). Also, as AF is a disease that may be caused by a wide range
of different factors and in turn, n−3 PUFA also has been ascribed
a long list of possible mechanisms of action on AF, the association
of effect is likely to vary between populations according to back-
ground intake of n−3 PUFA, the overall health status of patients,
and the type and duration of AF.
When comparing information from observational studies and
intervention studies, one must keep in mind that there are impor-
tant differences in the amounts of n−3 PUFA investigated in these
two types of designs. Observational studies often compare persons
with higher intakes against persons with very low intakes, whereas
in interventional studies a high dose is usually investigated against
a control group with an average intake that represents the whole
study population. For this reason, for example if there is a thresh-
old effect of n−3 PUFA between the lowest quartile of ﬁsh intake,
this may not be tested appropriately in a standard RCT. Likewise,
if there is an upper limit to the beneﬁcial effect of n−3 PUFA,
this could also be a problem in RCT where some persons are likely
to have a high background intake of ﬁsh supplemented with high
doses in capsules.
The concomitant treatment with other drugs that may poten-
tially work by some of the same mechanisms as n−3 PUFA may
also be relevant. Thus, in a recent study in patients with a his-
tory of myocardial infarction, low-dose supplementation with
n−3 fatty acids was associated with a reduction in major car-
diovascular events in patients not treated with statins, whereas in
statin users no difference was found (Eussen et al., 2012). Medica-
tions that affect atrial remodeling by reducing atrial ﬁbrosis and
also reduce AF may include statins and inhibitors of the renin–
angiotensin–aldosterone system (Nattel et al., 2008). It is possible
that the potential effect of additional treatment with n−3 PUFA
in these patients may be less.
A problem when studying AF is that while some patients are
bothered by symptoms of AF and therefore more likely to be
diagnosed, a large proportion are unaffected and only diagnosed
by chance or not at all. Also, even symptomatic patients have
asymptomatic episodes of AF. Thus, the proportions of sympto-
matic and asymptomatic patients vary between studies according
to the background population, and recurrence rates during follow-
up are increased depending on the completeness of heart rhythm
monitoring during follow-up (e.g., continuous or ambulant ECG)
which will have a major effect on the outcome and may explain
the diverging results obtained.
KEY QUESTIONS FOR FURTHER RESEARCH
Based on the available studies in regard to AF after cardiover-
sion or heart surgery, it seems reasonable to consider a pre-
procedure treatment of at least 30 days for interventional studies
examining the effect of dietary n−3 PUFA. Future studies are
needed to clarify whether a relation between dietary intake of
n−3 PUFA and AF is linear, U- or J-shaped or has a threshold
above which no further effect is obtained. More knowledge on
this has great implications both for comparing studies in pop-
ulations with different background dietary intake and dose of
exposure, and for establishing the optimal dosage. It is likely that
some conditions will have a higher potential for an effect of n−3
PUFA, and identifying these conditions would be important for
patient treatment. Experimental data suggest differences between
the acute effects of intravenous infusion of n−3 PUFA and the
chronic effects of dietary n−3 PUFA incorporated into cell mem-
branes, and therefore studies should be interpreted according to
the type of exposure. Finally, the endpoint in most studies is
ﬁrst episode of AF. Although this is a measurable endpoint, it
may well be that if only a small proportion can achieve free-
dom from AF, patients with AF would still be interested in a
treatment option that may reduce the number and severity of
episodes and burden of time in AF, as exempliﬁed by Biscione
et al. (2005).
CONCLUSION
There is growing evidence for an effect of marine n−3 PUFA
in prevention and treatment of AF. However, further studies are
needed to establish which patients are more likely to beneﬁt from
n−3 PUFA, timing of treatment, and dosages.
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